Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx věcí,

kterým xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx sděluje, xx xxx 1. října 2023 bylo xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx změn Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx v platnost x souladu x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx dne 18. června 2024 x nahradilo Přílohu X pro rok 2023, xxxxxxx od 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 a xxxx xxxxxxx xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., XX.X., x. r.

vrchní xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx antidopingovou agenturou (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx text Xxxxxxx xxxxxxxxxx látek x xxxxx bude xxxxxxxxx XXXX a xxxx publikován x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským textem xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx do konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, jak xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu. Xxxxx Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx látky a Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx méně důležité xxxx méně xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx o xxxxx x xxxxxx, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx použil x jinému xxxxx xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec xxxxxx. Xxxx Xxxxxxxx látky xxxx označovány xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx z následujících xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx orgánem xxx xxxxxxx použití x xxxx (např. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx nebo xxxxxxx xxxxx byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.

Tato xxxxx zahrnuje xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (androst-4-en-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými účinky.

S1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxxxx látky.

Následující látky x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X LÁTKY OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (TGF-β), např. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x xxxx, xxxx xxxx včetně:

• choriový xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (XX),

• hormon xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• kisspeptin x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Růstový xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x hGH 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:

• hormon xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx růstového xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF)

a xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxx xxxxx.

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Sportovec xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx X4.3 x X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx aktivin X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx myostatin (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, domagro zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (PPARδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (GW1516, XX501516) x xxxxxxxx Xxx-xxxɑ , např. SR9009, XX9011

X4.4.2 insuliny x xxxxxxxx insulinů

S4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx optických izomerů, xxxx. d- a x-, jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;

• Xxxxxxx, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx expandéry xxxxxxxx intravenózně, např.:

albumin, xxxxxxx, hydroxyetyl škrob, xxxxxxxx;

• Desmopresin;

• Probenecid;

a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx a xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx maskovací xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), bude xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx navíc k xx, která xxx xxxx udělena xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX METODY

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx xxxx Specifické xxxxxx.

X1. XXXXXXXXXX S XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx plazmy nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Umělé zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x modifikované xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx o podvod xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx xxxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx následující:

M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, které xxxxx změnit xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx xxxx x technologie xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky modifikovaných xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Specifické látky x výjimkou xxxxx xxxxxxxxx v X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x l-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, který xxxx xxxxxxxx uveden x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon a xxxx analogy, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x podobnou chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• klonidin;

• xxxxxxxx imidazolinu x xxxxxxx xxxxxx kožního, xxxxxxx, xxxxxx nebo xxxxxx použití (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (heroin)

Následující xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x l, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této xxxxx jsou Xxxxxxxxxx xxxxx. Návykové xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx přírodní x syntetické kanabinoidy xxxx xxxxxxxx, např.

• x xxxxxx (hašiš, xxxxxxxxx) a konopných xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (THC)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všechny glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx jakoukoliv xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx cestou.

Mimo jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx podání (včetně xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se používají x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx indikací.

P1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze v xxxxxxxxxxxxx sportech Xxx Xxxxxxx x xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / U-rampa x xxxxxxxxx U-rampa / xxx air

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx smlouvy v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx xxxxx xxx 150 mikrogramů x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx koncentraci x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml.

⁴⁾ epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou považovány xx Zakázané xxxxx.

Xxxxxxxxx

Xxxxxx předpis x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, pokud xx xxxx netýká xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx